Literature DB >> 25524384

Past, present and future targets for immunotherapy in ovarian cancer.

Carlton L Schwab1, Diana P English, Dana M Roque, Monica Pasternak, Alessandro D Santin.   

Abstract

Ovarian cancer is the leading cause of death from gynecologic malignancy in the US. Treatments have improved with conventional cytotoxic chemotherapy and advanced surgical techniques but disease recurrence is common and fatal in nearly all cases. Current evidence suggests that the immune system and its ability to recognize and eliminate microscopic disease is paramount in preventing recurrence. Ovarian cancer immunotherapy is targeting tumors through active, passive and adoptive approaches. The goal of immunotherapy is to balance the activation of the immune system against cancer while preventing the potential for tremendous toxicity elicited by immune modulation. In this paper we will review the different immunotherapies available for ovarian cancer as well as current ongoing studies and potential future directions.

Entities:  

Keywords:  CA125; EpCAM; NY-ESO-1; WT-1; adoptive transfer; mesothelin; ovarian cancer; p53; tumor associated antigens; tumor vaccines

Mesh:

Year:  2014        PMID: 25524384      PMCID: PMC4312614          DOI: 10.2217/imt.14.90

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  134 in total

1.  Localization of mesothelin in epithelial ovarian cancer.

Authors:  Raffit Hassan; Robert J Kreitman; Ira Pastan; Mark C Willingham
Journal:  Appl Immunohistochem Mol Morphol       Date:  2005-09

2.  Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125.

Authors:  Manish S Patankar; Yu Jing; Jamie C Morrison; Jennifer A Belisle; Frank A Lattanzio; Yuping Deng; Nyet Kui Wong; Howard R Morris; Anne Dell; Gary F Clark
Journal:  Gynecol Oncol       Date:  2005-08-29       Impact factor: 5.482

Review 3.  Self/non-self discrimination by human gammadelta T cells: simple solutions for a complex issue?

Authors:  Aurélie Thedrez; Caroline Sabourin; Julie Gertner; Marie-Claire Devilder; Sophie Allain-Maillet; Jean-Jacques Fournié; Emmanuel Scotet; Marc Bonneville
Journal:  Immunol Rev       Date:  2007-02       Impact factor: 12.988

Review 4.  Mesothelin-targeted agents in clinical trials and in preclinical development.

Authors:  Ronan J Kelly; Elad Sharon; Ira Pastan; Raffit Hassan
Journal:  Mol Cancer Ther       Date:  2012-02-17       Impact factor: 6.261

5.  Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Masaki Murakami; Manabu Hirai; Nobuhiko Tominaga; Hiroko Nakajima; Olga A Elisseeva; Tomoki Masuda; Akiko Nakano; Manabu Kawakami; Yusuke Oji; Kazuhiro Ikegame; Naoki Hosen; Keiko Udaka; Masaki Yasukawa; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

6.  Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D.

Authors:  Mathias Krockenberger; Yvonne Dombrowski; Claudia Weidler; Monika Ossadnik; Arnd Hönig; Sebastian Häusler; Heike Voigt; Jürgen C Becker; Lin Leng; Alexander Steinle; Michael Weller; Richard Bucala; Johannes Dietl; Jörg Wischhusen
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

7.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

8.  Naturally circulating dendritic cells to vaccinate cancer patients.

Authors:  Kalijn F Bol; Jurjen Tel; I Jolanda M de Vries; Carl G Figdor
Journal:  Oncoimmunology       Date:  2013-03-01       Impact factor: 8.110

9.  AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC.

Authors:  Chang-Xuan You; Min Shi; Yong Liu; Maohua Cao; Rongcheng Luo; Paul L Hermonat
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

10.  PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.

Authors:  Zhiqiang Guo; Xin Wang; Dali Cheng; Zhijun Xia; Meng Luan; Shulan Zhang
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more
  19 in total

Review 1.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

2.  Correlation Between Tumor Mesothelin Expression and Serum Mesothelin in Patients with Epithelial Ovarian Carcinoma: A Potential Noninvasive Biomarker for Mesothelin-targeted Therapy.

Authors:  Tatsuya Hanaoka; Kosei Hasegawa; Tomomi Kato; Sho Sato; Akira Kurosaki; Akiko Miyara; Shoji Nagao; Hiroyuki Seki; Masanori Yasuda; Keiichi Fujiwara
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

3.  Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma.

Authors:  Xiaoyan Ren; Yifei Liu; Yumei Tao; Guoxiang Zhu; Meilan Pei; Jianguo Zhang; Jian Liu
Journal:  Oncol Lett       Date:  2016-03-17       Impact factor: 2.967

4.  Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.

Authors:  David L Hermanson; Laura Bendzick; Lee Pribyl; Valarie McCullar; Rachel Isaksson Vogel; Jeff S Miller; Melissa A Geller; Dan S Kaufman
Journal:  Stem Cells       Date:  2015-12-06       Impact factor: 6.277

Review 5.  IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Ramesh B Batchu; Oksana V Gruzdyn; Bala K Kolli; Rajesh Dachepalli; Prem S Umar; Sameer K Rai; Namrata Singh; Pavan S Tavva; Donald W Weaver; Scott A Gruber
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

6.  Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.

Authors:  Kamila Kloudová; Hana Hromádková; Simona Partlová; Tomáš Brtnický; Lukáš Rob; Jiřina Bartůňková; Michal Hensler; Michael J Halaška; Radek Špíšek; Anna Fialová
Journal:  Oncotarget       Date:  2016-07-19

7.  HM015k, a Novel Silybin Derivative, Multi-Targets Metastatic Ovarian Cancer Cells and Is Safe in Zebrafish Toxicity Studies.

Authors:  Haneen Amawi; Noor A Hussein; Chandrabose Karthikeyan; Elangovan Manivannan; Alexander Wisner; Frederick E Williams; Temesgen Samuel; Piyush Trivedi; Charles R Ashby; Amit K Tiwari
Journal:  Front Pharmacol       Date:  2017-08-02       Impact factor: 5.810

8.  Prognostic implications of tumour-infiltrating lymphocytes for recurrence in epithelial ovarian cancer.

Authors:  Yuan Wu; Yue Gao; Lingxi Chen; Xin Jin; Pingbo Chen; Qingqing Mo
Journal:  Clin Exp Immunol       Date:  2021-07-14       Impact factor: 5.732

9.  Effect of targeted ovarian cancer immunotherapy using ovarian cancer stem cell vaccine.

Authors:  Di Wu; Jing Wang; Yunlang Cai; Mulan Ren; Yuxia Zhang; Fangfang Shi; Fengshu Zhao; Xiangfeng He; Meng Pan; Chunguang Yan; Jun Dou
Journal:  J Ovarian Res       Date:  2015-10-24       Impact factor: 4.234

Review 10.  Adoptive immunotherapy against ovarian cancer.

Authors:  Gloria Mittica; Sonia Capellero; Sofia Genta; Celeste Cagnazzo; Massimo Aglietta; Dario Sangiolo; Giorgio Valabrega
Journal:  J Ovarian Res       Date:  2016-05-17       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.